In the BioHarmony Drug Report Database

"Preview" Icon

Lifitegrast

Xiidra (lifitegrast) is a small molecule pharmaceutical. Lifitegrast was first approved as Xiidra on 2016-07-11. It is used to treat dry eye syndromes in the USA. The pharmaceutical is active against integrin alpha-L. Xiidra’s patents are valid until 2033-12-18 (FDA).

 

Trade Name

 

Xiidra
 

Common Name

 

lifitegrast
 

ChEMBL ID

 

CHEMBL2048028
 

Indication

 

dry eye syndromes
 

Drug Class

 

Antiasthmatics/antiallergics: integrin antagonists

Image (chem structure or protein)

Lifitegrast structure rendering